The drug safety scandals in recent weeks have underlined the risks to international consumers posed by weak oversight in China, the world’s largest supplier of active pharmaceutical ingredients.
Chinese manufacturers account for 40 per cent of the global production of such ingredients, according to the UK’s medicines regulator. It was an API was behind the first of the scandals in July.
The European Medicines Agency and the US Food and Drug Administration issued alerts over a cancer-causing ingredient used in a blood pressure medication, supplied by Chinese company Zhejiang Huahai, resulting in a recall of affected drugs.
您已閱讀11%（627字），剩余89%（5157字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。